OCUL Research | Milton Maxwell

OCUL

Ocular Therapeutix, Inc.

14.39

+0.22+1.55%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

-/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

3.07B

P/E (TTM)

Basic EPS (TTM)

-1.43

Dividend Yield

Recent Filings

8-K

NDA shift on single Phase 3

12/5/25Dec 5, 2025

Ocular Therapeutix plans to file an NDA for AXPAXLI in wet AMD using just year 1 data from its SOL-1 Phase 3 trial, ditching the FDA's traditional two-trial norm after recent agency signals. Top-line results hit Q1 2026. FDA alignment isn't guaranteed.

10-Q

Q3 FY2025 results

11/4/25Nov 4, 2025

Ocular Therapeutix posted Q3 revenue of $14.5M, down 5% y/y from $15.4M yet with in-market DEXTENZA units up 6,000 to 48,000 amid Medicare reimbursement pressures. R&D surged 41% y/y to $52.4M, driven by $34.7M on AXPAXLI wet AMD trials (SOL-1, SOL-R), fueling a $68.7M operating loss—wider than $46.0M y/y—while net loss hit $69.4M versus $36.5M, the gap due to fair-value changes in derivative liabilities. Cash sits at $344.8M with $70.6M net debt (Barings term loan due 2029); October's $445M offering bolsters runway. SOL-1 nears Q1 2026 readout. Clinical trial delays loom large.

8-K

Q3 results: revenue dips, trials advance

11/4/25Nov 4, 2025

Ocular Therapeutix reported Q3 net revenue of $14.5M, down 5.8% from $15.4M last year due to DEXTENZA reimbursement headwinds, yet unit sales rose 9.7% sequentially. R&D expenses jumped to $52.4M from $37.1M amid SOL-1/SOL-R trials; SOL-R hit 555-subject target with topline data on track for 1H 2027. Cash stands at $344.8M plus ~$445M from October offering. Runway extends into 2028.

8-K

OCUL prices $446M stock offering

9/30/25Sep 30, 2025

Ocular Therapeutix priced an underwritten offering of 37,909,018 common shares at $12.53 each on September 30, 2025, expecting to close October 1 and raise net proceeds of $445.9 million. The funds will support AXPAXLI's open-label extension for wet AMD, Phase 3 trials for NPDR, manufacturing investments, and pre-commercialization efforts. Cash runway extends into 2028, yet excludes full AXPAXLI launch costs. Assumptions may falter.

8-K

AXPAXLI program updates announced

9/30/25Sep 30, 2025

Ocular Therapeutix announced updates on September 30, 2025, for its AXPAXLI program targeting wet AMD and NPDR. The SOL-1 Phase 3 trial completed randomization of 344 subjects and boasts over 95% retention with no new safety signals; topline data expected Q1 2026. SOL-R enrollment finished, results due first half 2027. Plans for HELIOS-2 and HELIOS-3 Phase 3 trials in NPDR secured FDA SPA agreements. A new U.S. patent allowance extends IP to 2044. Trials advance, but outcomes remain uncertain.

About

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

CEO

Dr. Pravin U. Dugel M.D.

IPO

7/25/2014

Website

https://www.ocutx.com

Employees

274

Sector

Healthcare

Industry

Biotechnology